Drug Profile
Research programme: therapeutic agents - Tasly-SemBioSys
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator SemBioSys Genetics
- Developer Tasly-SemBioSys Pharmaceuticals
- Class
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diabetes mellitus; Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Diabetes-mellitus in China
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in China
- 31 May 2012 Tianjin Tasly Pharmaceutical is now called Tasly Pharmaceutical Group